In this interview, David Flores sits down with Cody Shandraw, the managing partner at Ambria Capital.
Ambria Capital is an investment firm which focuses on investing in psychedelic therapies and technologies. In this episode they discuss the psychedelic space in general and Ambria’s approach to investing.
Cody acknowledges that many companies in the space will fail, but the ones who succeed will transform the mental health landscape. That is a risk that Ambria Capital is willing to take to be involved in the psychedelic transformation that is unfolding.
Psychedelics are changing people’s lives, and Ambria Capital wants to make sure that these companies are financed to do so…And maybe make some money on the successful companies.
Cody acknowledges that his family has had lots of addiction issues, so this issue is personal for him. If psychedelics can help addiction, it would be a game changer.
Cody discusses how the most important thing for deciding which company to invest in, is the management teams, regardless of whether they work with psilocybin, lsd, mescaline or other compounds.
Cody really likes PsyHealth.
We all know someone who has been affected by addiction, depression, anxiety, or other mental health issues. We all want to find solutions to help these people.
#AmbriaCapital #Psychedelics #PsychedelicTherapy
source
![Important UPDATE : MindMed’s 2020 Year-End Financial Results [ Good News for MMED / MMEDF! ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-91-600x338.jpeg)
![This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-33-600x338.jpeg)